Table 1.
Characteristics of studies included in the meta-analysis.
| Author | Year | Study period | Country | Mean age (Y) | FIGO stage | No. patients | Ovarian preservation (n) | Oophorectomy (n) | Rate of ovarian metastases | Survival outcome reported |
|---|---|---|---|---|---|---|---|---|---|---|
| Hopkins et al. (22) | 1987 | 1970–1984 | US | NA | I | 24 | 8 | 16 | 0/16 | OS |
| Angel et al. (12) | 1992 | 1966–1990 | US | 47 | I | 59 | 41 | 18 | 0/41 | OS, PFS |
| Sutton et al. (13) | 1992 | 1981–1984 | GOG | NA | I | 121 | 41 | 80 | 2/80 (2.5%) | PFS |
| Kasamatsu et al. (9) | 2009 | 1984–2003 | Japan | 48 | I-II | 123 | 22 | 100 | 6/100 (6%) | OS, PFS |
| Chen et al. (7) | 2016 | 1999–2013 | China | 43.6 | I-II | 194 | 33 | 153 | 5/153 (3.3%) | OS, PFS |
| Ruengkhachorn et al. (23) | 2016 | 2006–2013 | Thailand | 44.9 | I | 35 | 16 | 19 | 0/19 | PFS |
| Matsuo et al. (24) | 2017 | 1983–2012 | SEER | 45.3 | I | 4,019 | 960 | 3,059 | NA | OS |
| Hu et al. (25) | 2017 | 1994–2015 | China | 46.2 | I–II | 105 | 19 | 86 | 3/86 (3.5%) | OS |
| Xie et al. (26) | 2018 | 2003–2015 | China | 44.3 | I–II | 128 | 15 | 113 | 1/113 (0.9%) | OS |
| Guo et al. (27) | 2018 | 1995–2017 | China | NA | I–II | 267 | 44 | 223 | 13/223 (5.8%) | PFS |
| Total | – | – | – | 45.6 | – | 5,075 | 1,199 | 3,867 | 30/831 (3.61%) | – |
FIGO, International Federation of Gynecology and Obstetrics; GOG, Gynecologic Oncology Group; NA, not available; OS, overall survival; PFS, progression free survival.